FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897598359> ?p ?o ?g. }

• W2897598359 endingPage "e183023" @default.
• W2897598359 startingPage "e183023" @default.
• W2897598359 abstract "Chemotherapy is a mainstay treatment of metastatic non-small cell lung cancer. However, little is known about the comparative risk of hospitalization associated with commonly used chemotherapy regimens.To evaluate the real-world association of specific lung cancer chemotherapy regimens with measures of acute hospital care (primary objective) and survival (secondary objective).Retrospective, propensity-matched, cohort study using the Surveillance, Epidemiology, and End Results-Medicare linked data for cancer diagnoses between 2008 and 2013, with follow-up through 2014. Patients were Medicare beneficiaries 66 years of age or older receiving initial chemotherapy for treatment of stage IV, nonsquamous, non-small cell lung cancer. Analyses were performed between September 2017 and April 2018.Receipt of chemotherapy with carboplatin-pemetrexed or carboplatin-paclitaxel, with or without concurrent bevacizumab.The primary outcome was risk of hospitalization within 30 days of chemotherapy initiation. Secondary measures included cumulative 90-day hospitalizations, 90-day mean hospital-free survival time, and overall survival.Of the 3310 eligible patients, 1823 received carboplatin-pemetrexed, and 1487 received carboplatin-paclitaxel. The median age at diagnosis was 73 years (interquartile range, 69-77 years), 1784 patients (53.9%) were men, and 2909 patients (87.9%) were non-Hispanic white. In total, 2182 patients were included in the propensity-matched analysis. The 30-day hospitalization risk was 20.7% (95% CI, 18.3%-23.1%) among patients receiving carboplatin-pemetrexed vs 26.0% (95% CI, 23.4%-28.6%) among patients receiving carboplatin-paclitaxel (5.3% difference; P = .003). The 90-day cumulative hospitalizations did not differ significantly between the 2 treatment groups; however, the 90-day mean hospital-free survival time was improved for patients receiving carboplatin-pemetrexed (68.4 days [95% CI, 66.5-70.4 days] vs 63.6 days [95% CI, 61.6-65.7 days]; P = .001). The median survival time was 9.0 months (95% CI, 8.4-9.5 months) with carboplatin-pemetrexed therapy vs 7.6 months (95% CI, 7.0-8.4 months) with carboplatin-paclitaxel therapy (P = .005). Stratified analyses showed no association of bevacizumab use with hospitalization risk or survival when combined with either chemotherapy regimen.The findings from this study suggest that patients receiving carboplatin-pemetrexed compared with those receiving carboplatin-paclitaxel have a lower 30-day hospitalization risk, a greater 90-day hospital-free survival, and improved overall survival. Information about hospitalization risk may provide valuable context for evaluating real-world cancer treatment outcomes." @default.
• W2897598359 created "2018-10-26" @default.
• W2897598359 creator A5031338214 @default.
• W2897598359 creator A5038929684 @default.
• W2897598359 creator A5052728393 @default.
• W2897598359 creator A5075264942 @default.
• W2897598359 creator A5077058201 @default.
• W2897598359 creator A5088893766 @default.
• W2897598359 date "2018-10-05" @default.
• W2897598359 modified "2023-10-17" @default.
• W2897598359 title "Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer" @default.
• W2897598359 cites W1968661751 @default.
• W2897598359 cites W1978315939 @default.
• W2897598359 cites W1995580600 @default.
• W2897598359 cites W2000445173 @default.
• W2897598359 cites W2014516834 @default.
• W2897598359 cites W2031186895 @default.
• W2897598359 cites W2036193982 @default.
• W2897598359 cites W2037139573 @default.
• W2897598359 cites W2040253672 @default.
• W2897598359 cites W2045805729 @default.
• W2897598359 cites W2085791471 @default.
• W2897598359 cites W2099725888 @default.
• W2897598359 cites W2104616343 @default.
• W2897598359 cites W2106664438 @default.
• W2897598359 cites W2107694321 @default.
• W2897598359 cites W2111635289 @default.
• W2897598359 cites W2126049444 @default.
• W2897598359 cites W2145835533 @default.
• W2897598359 cites W2148367564 @default.
• W2897598359 cites W2150275080 @default.
• W2897598359 cites W2153434255 @default.
• W2897598359 cites W2157358083 @default.
• W2897598359 cites W2171231883 @default.
• W2897598359 cites W2469750590 @default.
• W2897598359 cites W2518271475 @default.
• W2897598359 cites W2527905628 @default.
• W2897598359 cites W2572130814 @default.
• W2897598359 cites W2740070722 @default.
• W2897598359 cites W2760699482 @default.
• W2897598359 cites W2796582438 @default.
• W2897598359 cites W4245188527 @default.
• W2897598359 doi "https://doi.org/10.1001/jamanetworkopen.2018.3023" @default.
• W2897598359 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324452" @default.
• W2897598359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646220" @default.
• W2897598359 hasPublicationYear "2018" @default.
• W2897598359 type Work @default.
• W2897598359 sameAs 2897598359 @default.
• W2897598359 citedByCount "5" @default.
• W2897598359 countsByYear W28975983592019 @default.
• W2897598359 countsByYear W28975983592020 @default.
• W2897598359 countsByYear W28975983592021 @default.
• W2897598359 countsByYear W28975983592022 @default.
• W2897598359 countsByYear W28975983592023 @default.
• W2897598359 crossrefType "journal-article" @default.
• W2897598359 hasAuthorship W2897598359A5031338214 @default.
• W2897598359 hasAuthorship W2897598359A5038929684 @default.
• W2897598359 hasAuthorship W2897598359A5052728393 @default.
• W2897598359 hasAuthorship W2897598359A5075264942 @default.
• W2897598359 hasAuthorship W2897598359A5077058201 @default.
• W2897598359 hasAuthorship W2897598359A5088893766 @default.
• W2897598359 hasBestOaLocation W28975983591 @default.
• W2897598359 hasConcept C119060515 @default.
• W2897598359 hasConcept C126322002 @default.
• W2897598359 hasConcept C143998085 @default.
• W2897598359 hasConcept C167135981 @default.
• W2897598359 hasConcept C2776256026 @default.
• W2897598359 hasConcept C2776694085 @default.
• W2897598359 hasConcept C2777240266 @default.
• W2897598359 hasConcept C2777802072 @default.
• W2897598359 hasConcept C2778239845 @default.
• W2897598359 hasConcept C2781451048 @default.
• W2897598359 hasConcept C71924100 @default.
• W2897598359 hasConceptScore W2897598359C119060515 @default.
• W2897598359 hasConceptScore W2897598359C126322002 @default.
• W2897598359 hasConceptScore W2897598359C143998085 @default.
• W2897598359 hasConceptScore W2897598359C167135981 @default.
• W2897598359 hasConceptScore W2897598359C2776256026 @default.
• W2897598359 hasConceptScore W2897598359C2776694085 @default.
• W2897598359 hasConceptScore W2897598359C2777240266 @default.
• W2897598359 hasConceptScore W2897598359C2777802072 @default.
• W2897598359 hasConceptScore W2897598359C2778239845 @default.
• W2897598359 hasConceptScore W2897598359C2781451048 @default.
• W2897598359 hasConceptScore W2897598359C71924100 @default.
• W2897598359 hasIssue "6" @default.
• W2897598359 hasLocation W28975983591 @default.
• W2897598359 hasLocation W28975983592 @default.
• W2897598359 hasLocation W28975983593 @default.
• W2897598359 hasLocation W28975983594 @default.
• W2897598359 hasOpenAccess W2897598359 @default.
• W2897598359 hasPrimaryLocation W28975983591 @default.
• W2897598359 hasRelatedWork W2003200862 @default.
• W2897598359 hasRelatedWork W2049286103 @default.
• W2897598359 hasRelatedWork W2333409521 @default.
• W2897598359 hasRelatedWork W2347478140 @default.
• W2897598359 hasRelatedWork W2380561034 @default.
• W2897598359 hasRelatedWork W2381236910 @default.
• W2897598359 hasRelatedWork W2522002668 @default.

• next